First personalized cancer vaccine prevents recurrence

A major clinical trial has found that a personalized cancer vaccine, used alongside an immunotherapy drug, reduced the risk of melanoma recurrence and spread by 42% over two years. The vaccine, called Intismeran, uses patient-specific tumor information and is based on mRNA technology similar to COVID-19 vaccines. Results also showed a 38% reduction in melanoma spread, with long-term benefits still under investigation. The findings are seen as a potential breakthrough in personalized cancer treatment, pending further studies and regulatory approval.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل